Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,102 active trials29 approved drugs653 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,789 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07346105 | Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies | available | — | — | Orca Biosystems, Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05738538 | Expanded Access to Ziftomenib | available | — | — | Kura Oncology, Inc.INDUSTRY | 0 | Jun 29, 2026 | clinicaltrials |
| Individual Patient Compassionate Use of Mirdametinib |
| available |
| — |
| — |
| SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY |
| 0 |
| May 8, 2026 |
| clinicaltrials |
| NCT05593185 | Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS | available | — | — | Sellas Life Sciences GroupINDUSTRY | 0 | Apr 24, 2026 | clinicaltrials |
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor(KEAP) | available | — | — | Karyopharm Therapeutics IncINDUSTRY | 0 | Mar 2, 2026 | clinicaltrials |
| NCT03123029 | Expanded Access to Venetoclax | available | — | — | AbbVieINDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT04745637 | Managed Access Programs for INC424, Ruxolitinib | available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 18, 2025 | clinicaltrials |
| NCT00854841 | The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder | available | — | — | Pusan National University HospitalOTHER | 0 | Mar 3, 2009 | clinicaltrials |
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials